<DOC>
	<DOCNO>NCT01248936</DOCNO>
	<brief_summary>This open-label , non-comparative , multicenter , expand access study RO5185426 patient receive prior systemic therapy metastatic melanoma satisfactory treatment option .</brief_summary>
	<brief_title>A Study RO5185426 Patients With Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically confirm metastatic melanoma document BRAF V600E mutation , determine cobas BRAF V600 mutation test Patients either measurable nonmeasurable disease Adequate recovery recent systemic local treatment metastatic melanoma Adequate organ function For woman childbearing potential , agreement use two acceptable method contraception , include one barrier method , study 6 month discontinuation RO5185426 For men female partner childbearing potential , agreement use latex condom , advise female partner use additional method contraception study 6 month discontinuation RO5185426 Negative serum urine pregnancy test within 7 day commencement treatment premenopausal woman . Women either surgically sterile postmenopausal least 1 year eligible participate study Agreement donate blood blood product study least 6 month discontinuation RO5185426 ; male patient , agreement donate sperm study least 6 month discontinuation RO5185426 Pregnant breastfeed Concurrent antitumor therapy Uncontrolled medical illness History congenital prolong QT syndrome patient mean QTc interval great 470 millisecond baseline , ongoing grade 2 great cardiac arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>